- Home
- ADI vs SNY Comparison
ADI vs SNY Comparison
Compare ADI & SNY Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ADI
- SNY
- Stock Information
- Founded
- ADI 1965
- SNY 1994
- Country
- ADI United States
- SNY France
- Employees
- ADI N/A
- SNY N/A
- Industry
- ADI Semiconductors
- SNY Biotechnology: Pharmaceutical Preparations
- Sector
- ADI Technology
- SNY Health Care
- Exchange
- ADI Nasdaq
- SNY Nasdaq
- Market Cap
- ADI 115.2B
- SNY 116.1B
- IPO Year
- ADI 1972
- SNY N/A
- Fundamental
- Price
- ADI $234.39
- SNY $49.66
- Analyst Decision
- ADI Buy
- SNY Buy
- Analyst Count
- ADI 22
- SNY 4
- Target Price
- ADI $270.00
- SNY $61.50
- AVG Volume (30 Days)
- ADI 3.5M
- SNY 2.2M
- Earning Date
- ADI 11-25-2025
- SNY 10-24-2025
- Dividend Yield
- ADI 1.70%
- SNY 3.22%
- EPS Growth
- ADI 18.69
- SNY 105.93
- EPS
- ADI 3.93
- SNY 8.67
- Revenue
- ADI $10,386,795,000.00
- SNY $53,890,648,839.00
- Revenue This Year
- ADI $17.28
- SNY $2.37
- Revenue Next Year
- ADI $13.28
- SNY $6.51
- P/E Ratio
- ADI $59.12
- SNY $11.30
- Revenue Growth
- ADI 7.08
- SNY N/A
- 52 Week Low
- ADI $158.65
- SNY $44.62
- 52 Week High
- ADI $258.13
- SNY $60.12
- Technical
- Relative Strength Index (RSI)
- ADI 48.56
- SNY 45.96
- Support Level
- ADI $224.25
- SNY $48.73
- Resistance Level
- ADI $235.28
- SNY $52.67
- Average True Range (ATR)
- ADI 6.46
- SNY 0.75
- MACD
- ADI -0.19
- SNY -0.25
- Stochastic Oscillator
- ADI 53.75
- SNY 25.27
About ADI Analog Devices Inc.
Analog Devices is a leading analog, mixed-signal, and digital-signal processing chipmaker. The firm has a significant market share lead in converter chips, which are used to translate analog signals to digital and vice versa. The company serves tens of thousands of customers; more than half of its chip sales are to industrial and automotive end markets. ADI's chips are also incorporated into wireless infrastructure equipment.
About SNY Sanofi ADS
Sanofi develops and markets drugs with a concentration in immunology, vaccines, and rare diseases. Although the company offers a diverse array of drugs, its highest revenue generator, Dupixent, accounts for approximately 30% of total sales. Profits for this immunology blockbuster drug are shared with Regeneron. About 45% of total revenue comes from the United States, 20% from Europe, and 6% from China.